CTOs on the Move

Chimerix

www.chimerix.com

 
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix`s proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.chimerix.com
  • 2505 Meridian Parkway Suite 100
    Durham, NC USA 27713
  • Phone: 919.806.1074

Executives

Name Title Contact Details
Roy Ware
Chief Manufacturing and Technology Officer Profile

Funding

Chimerix raised $100M on 01/21/2021

Similar Companies

BestCo

BestCo is a leading developer and manufacturer of innovative pharmaceutical dosage forms for the OTC (Over-the-Counter) Drug, Vitamin and Supplement marketplace.

Falks Woodland Pharmacy

Falks Woodland Pharmacy is a Duluth, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Celera Corporation

Celera Corporation (Celera) is a healthcare business delivering personalized disease management through a combination of products and services. The Company operates in three segments: a clinical laboratory testing service business (Lab Services), a

Invagen Pharmaceuticals Inc

Invagen Pharmaceuticals Inc is a Hauppauge, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Berg Pharma

Berg Pharma focuses research on understanding how alterations in metabolism relate to disease onset. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the Berg Interrogative Biology™ discovery platform that translates biological output into therapeutic candidates, Berg Pharma is well positioned for rapid commercialization of its intellectual capital.